Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes melli
Legend: Unadjusted and adjusted hazard ratios (HR) and 95% Confidence Intervals (CI) for end-stage renal disease (ESRD) and death associated with 1 unit (µmol/L) change in homoarginine. (‡) Relative r
BackgroundClinical practice guidelines support an early invasive approach after NSTE-ACS in patients with chronic kidney disease (CKD). There is no direct randomised controlled trial evidence in the C
